Montelukast Viatris

Montelukast, the active ingredient in Montelukast Viatris, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is employed to manage chronic asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children. The medication is indicated for long‑term maintenance therapy and is available in EU markets under strict pharmacovigilance standards.

GNH USA supplies Montelukast Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured manufacturing and regulatory expertise across multiple markets.

Montelukast acts on leukotriene pathways to control airway inflammation and allergic symptoms.

Asthma: provides maintenance therapy that reduces frequency of exacerbations and improves lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal or perennial allergies. Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity, allowing better exercise tolerance.

Montelukast may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often transient - Abdominal pain: discomfort or cramps in the stomach area - Cough: occasional dry cough - Nausea: feeling of queasiness - Fatigue: general tiredness - Dizziness: light‑headed sensation

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips or throat - Mood changes or suicidal thoughts: new or worsening depression or suicidal ideation - Severe skin rash (Stevens‑Johnson syndrome): painful blistering skin eruption - Hepatic injury: signs of liver dysfunction such as jaundice - Anaphylaxis: severe allergic reaction with breathing difficulty - Blood dyscrasias (e.g., neutropenia): abnormal low white‑blood‑cell counts

When prescribing Montelukast, clinicians should consider several precautionary measures to ensure safe use.

- Assess liver function: monitor hepatic enzymes in patients with liver disease - Avoid use in patients with known hypersensitivity: discontinue if allergic reaction occurs - Use caution in patients with psychiatric disorders: watch for mood changes or suicidal thoughts - Consider dose adjustment in severe renal impairment: renal clearance may be reduced - Store at ambient temperature: keep in original packaging, protect from moisture

Montelukast can interact with other medicines, affecting its plasma levels or therapeutic outcomes.

Major Interactions (Avoid): - Ritonavir: potent CYP3A4 inhibitor may increase montelukast exposure, risk of toxicity - Phenobarbital: strong CYP inducer may lower montelukast levels, reducing efficacy

Moderate Interactions (Monitor Closely): - Corticosteroids: additive anti‑inflammatory effect may require monitoring - Beta‑agonists: possible reduced bronchodilator response when combined - Warfarin: may alter anticoagulant effect, monitor INR